Form 4: Cabaletta Bio CEO Granted 674,000 Stock Options

Cabaletta Bio's President and CEO, Steven Nichtberger, was granted 674,000 stock options with a $3.3 exercise price and a multi-year vesting schedule.

Summary

• Steven Nichtberger, President & CEO and Director of Cabaletta Bio, Inc. (CABA), acquired 674,000 derivative securities in the form of stock options.
• The transaction date for the grant was March 2, 2026.
• Each option has an exercise price of $3.30.
• The options have an expiration date of March 1, 2036.
• The vesting schedule dictates that 25% of the shares underlying the option will vest and become exercisable on March 1, 2027, with the remaining shares vesting in twelve substantially equal quarterly installments thereafter.
• Vesting is contingent upon Mr. Nichtberger's continued service to the company.
• Following this transaction, Mr. Nichtberger beneficially owns 674,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive compensation practice that aligns management's long-term interests with shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the interests of President & CEO Steven Nichtberger with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Negatives

• No direct negatives are indicated by this routine insider transaction filing.

Risks

• No specific risks are detailed within this Form 4 filing.

Future Outlook

The vesting schedule for the stock options extends through March 2027 and beyond, indicating an expectation of continued service from President & CEO Steven Nichtberger and a long-term incentive structure tied to future company performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to executive leadership is a standard practice in the biotechnology and broader corporate sectors, serving as a key component of executive compensation packages designed to align management incentives with shareholder value creation over the long term.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common executive compensation tool, comparable to practices at peer biotechnology companies such as Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX), which frequently use equity awards to retain and incentivize key personnel.
• The exercise price of $3.30, likely the closing price on the grant date, is standard for at-the-money option grants.
• A 10-year expiration period is typical for such long-term incentive options in the industry.

Stakeholder Impact

• Shareholders: The grant aims to align management's incentives with shareholder interests, potentially leading to improved long-term performance. Dilution from future option exercise is a consideration, but it's a standard part of equity compensation.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: Steven Nichtberger receives a significant long-term incentive, tying a portion of his future compensation directly to the company's stock performance.

Next Steps

• Continued service of Steven Nichtberger to facilitate vesting of options.
• Future vesting dates for the remaining stock options, starting March 1, 2027, and continuing quarterly thereafter.

Key Dates

Keywords

Cabaletta Bio, CABA, Steven Nichtberger, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Biotechnology